Crossref journal-article
S. Karger AG
Chemotherapy (127)
Abstract

Cancer cells require a steady source of metabolic energy in order to continue their uncontrolled growth and proliferation. Accelerated glycolysis is one of the biochemical characteristics of cancer cells. Recent work indicates that glucose transport and metabolism are essential for the posttreatment survival of tumor cells, leading to poor prognosis. Glycolytic breakdown of glucose is preceded by the transport of glucose across the cell membrane, a rate-limiting process mediated by facilitative glucose transporter proteins belonging to the facilitative glucose transporter/solute carrier GLUT/SLC2A family. Tumors frequently show overexpression of GLUTs, especially the hypoxia-responsive GLUT1 and GLUT3 proteins. There are also studies that have reported associations between GLUT expression and proliferative indices, whilst others suggest that GLUT expression may be of prognostic significance. In this article we revisit Warburg’s original hypothesis and review the recent clinical and basic research on the expression of GLUT family members in human cancers and in cell lines derived from human tumors. We also explore the links between hypoxia-induced genes, glucose transporters and angiogenic factors. Hypoxic tumors are significantly more malignant, metastatic, radio- and chemoresistant and have a poor prognosis. With the discovery the oxygen-sensitive transcription factor hypoxia-inducible factor (HIF-1) has come a new understanding of the molecular link between hypoxia and deregulated glucose metabolism. HIF-1 induces a number of genes integral to angiogenesis, e.g. vascular endothelial growth factor (VEGF), a process intimately involved with metastatic spread. This knowledge may enhance existing chemotherapeutic strategies so that treatment can be more rationally applied and personalized for cancer patients.

Bibliography

Airley, R. E., & Mobasheri, A. (2007). Hypoxic Regulation of Glucose Transport, Anaerobic Metabolism and Angiogenesis in Cancer: Novel Pathways and Targets for Anticancer Therapeutics. Chemotherapy, 53(4), 233–256. Portico.

Authors 2
  1. Rachel E. Airley (first)
  2. Ali Mobasheri (additional)
References 134 Referenced 262
  1. 10.2307%2F2530600
  2. 10.1016%2F0278-6915%2886%2990346-7
  3. 10.1016%2Fj.canlet.2004.02.009
  4. 10.1093%2Fcarcin%2F21.3.497
  5. 10.1126%2Fscience.123.3191.309
  6. 10.4067%2FS0716-97602002000100004
  7. 10.1016%2Fj.ejca.2003.10.024
  8. 10.1007%2FBF02904704
  9. 10.1007%2Fs00259-005-0044-8
  10. 10.1016%2F0197-0186%2893%2990004-O
  11. 10.1079%2FBJN2002763
  12. 10.1080%2F09687680110090456
  13. 10.1111%2Fj.1432-1033.1994.tb18550.x
  14. 10.1080%2F09687680110100995
  15. 10.1016%2F0006-291X%2892%2992362-2
  16. 10.1210%2Fen.132.6.2538
  17. 10.1073%2Fpnas.86.8.2535
  18. 10.1093%2Femboj%2F20.16.4467
  19. 10.1006%2Fgeno.2002.7010
  20. 10.1046%2Fj.1440-1827.2002.01368.x
  21. 10.1007%2Fs00066-003-1150-9
  22. 10.1002%2F1097-0142%2819931115%2972%3A10%3C2979%3A%3AAID-CNCR2820721020%3E3.0.CO%3B2-X
  23. 10.1309%2F5Y2L-CDCK-YB55-KDK6
  24. 10.1073%2Fpnas.93.5.1847
  25. 10.1002%2F%28SICI%291097-0142%2819980701%2983%3A1%3C34%3A%3AAID-CNCR5%3E3.0.CO%3B2-E
  26. 10.1159%2F000055314
  27. 10.1038%2Fsj.bjc.6601202
  28. 10.1002%2Fijc.2910560503
  29. 10.1002%2Fcncr.11159
  30. 10.1002%2F%28SICI%291097-0142%2819970915%2980%3A6%3C1046%3A%3AAID-CNCR6%3E3.0.CO%3B2-7
  31. 10.1016%2FS0169-5002%2802%2900108-3
  32. 10.1002%2F1097-0142%2820010801%2992%3A3%3C634%3A%3AAID-CNCR1364%3E3.0.CO%3B2-X
  33. 10.1089%2F105072502760339307
  34. 10.1016%2F0169-328X%2894%2990183-X
  35. 10.1023%2FA%3A1026466229242
  36. 10.1002%2Fcncr.10280
  37. 10.1006%2Fgyno.2000.5910
  38. 10.1002%2F1097-0142%2820010901%2992%3A5%3C1144%3A%3AAID-CNCR1432%3E3.0.CO%3B2-T
  39. 10.1016%2F0006-291X%2890%2991263-R
  40. 10.1097%2F00005537-200202000-00034
  41. 10.1080%2F09553009214552291
  42. 10.1002%2F%28SICI%291097-0142%2820000115%2988%3A2%3C381%3A%3AAID-CNCR20%3E3.0.CO%3B2-M
  43. 10.1002%2Fijc.1336
  44. 10.1054%2Fbjoc.2000.1305
  45. 10.1126%2Fscience.3839598
  46. 10.1016%2F0167-8140%2893%2990025-4
  47. 10.1634%2Ftheoncologist.7-6-492
  48. 10.1016%2FS0167-8140%2898%2900044-9
  49. 10.2307%2F3574011
  50. 10.1269%2Fjrr.43.161
  51. 10.1097%2F00001813-200101000-00001
  52. 10.1007%2FBF00689633
  53. 10.1016%2F0014-5793%2879%2981037-6
  54. 10.1093%2Fjnci%2F93.4.266
  55. 10.1080%2F028418699432590
  56. 10.1054%2Fdrup.2000.0120
  57. 10.1054%2Fbjoc.2000.1564
  58. 10.3109%2F02841869609100716
  59. 10.1016%2FS1053-4296%2896%2980033-6
  60. 10.1053%2Fsrao.2003.50008
  61. 10.1073%2Fpnas.94.9.4273
  62. 10.1073%2Fpnas.95.14.7987
  63. 10.1074%2Fjbc.271.50.32253
  64. 10.1074%2Fjbc.271.51.32529
  65. 10.1073%2Fpnas.94.15.8104
  66. 10.1038%2Fsj.onc.1205047
  67. 10.1006%2Fabbi.1996.0469
  68. 10.1074%2Fjbc.271.48.30392
  69. 10.1016%2F0005-2736%2889%2990205-8
  70. 10.1023%2FA%3A1022446730452
  71. 10.1074%2Fjbc.C000023200
  72. 10.1016%2FS0014-5793%2897%2900340-2
  73. 10.1074%2Fjbc.M010144200
  74. 10.1259%2F0007-1285-64-760-350
  75. 10.1128%2FMCB.21.10.3436-3444.2001
  76. 10.1074%2Fjbc.272.9.5555
  77. 10.1016%2FS0272-6386%2899%2970131-9
  78. 10.1021%2Fbi00447a011
  79. 10.1021%2Fbi961208t
  80. 10.1006%2Fbbrc.1999.1040
  81. 10.1200%2FJCO.20.2.379
  82. 10.1016%2FS0006-2952%2802%2901160-7
  83. 10.1210%2Fen.142.6.2707
  84. 10.1038%2Fsj.gt.3301702
  85. 10.1016%2FS0360-3016%2898%2900323-X
  86. 10.1016%2F0360-3016%2896%2900132-0
  87. 10.1016%2FS0360-3016%2898%2900004-2
  88. 10.1038%2Fsj.bjc.6690700
  89. 10.1159%2F000088950
  90. 10.1080%2F02841860152708198
  91. 10.1006%2Fgyno.1998.5163
  92. 10.1016%2FS0167-8140%2897%2901931-2
  93. 10.2307%2F3580034
  94. 10.1016%2FS0167-8140%2803%2900010-0
  95. 10.1016%2FS0360-3016%2800%2901493-0
  96. 10.1002%2Fijc.10904
  97. 10.2307%2F3579620
  98. 10.1054%2Fbjoc.2000.1111
  99. 10.1097%2F00006231-199802000-00002
  100. 10.1016%2FS0959-8049%2800%2900031-9
  101. 10.1016%2FS0969-8051%2897%2900226-6
  102. 10.1016%2FS0969-8051%2802%2900288-3
  103. 10.1016%2F0969-8051%2894%2990162-7
  104. 10.1007%2Fs002590050197
  105. 10.1007%2Fs002590050355
  106. 10.1097%2F00004424-200305000-00002
  107. 10.3816%2FCBC.2003.s.016
  108. 10.1016%2FS1095-0397%2800%2900042-X
  109. 10.1007%2Fs00259-003-1127-z
  110. 10.1097%2F00006231-200108000-00005
  111. 10.1097%2F00004424-198705000-00002
  112. 10.1016%2FS0959-8049%2800%2900037-X
  113. 10.1016%2FS0969-8051%2896%2900134-5
  114. 10.1007%2FBF01052932
  115. 10.1080%2F028418600750013320
  116. 10.1007%2Fs00259-003-1130-4
  117. 10.1007%2Fs00259-002-1096-7
  118. 10.1016%2FS0969-8043%2802%2900186-0
  119. 10.1038%2F19986
  120. 10.1016%2FS0006-8993%2801%2902877-3
  121. 10.1046%2Fj.1432-1327.1999.00403.x
  122. 10.1038%2F364079a0
  123. 10.1074%2Fjbc.272.30.18982
  124. 10.1074%2Fjbc.M110496200
  125. 10.1021%2Fjm991119p
  126. 10.1159%2F000238451
  127. 10.1016%2FS0046-8177%2800%2980192-6
  128. 10.1046%2Fj.1471-4159.1999.0720238.x
  129. 10.1074%2Fjbc.M312226200
  130. 10.1016%2FS0022-5193%2805%2980200-0
  131. 10.1146%2Fannurev.ge.22.120188.002513
  132. 10.1146%2Fannurev.cellbio.15.1.551
  133. 10.1007%2FBF00268936
  134. 10.1016%2F0005-2736%2891%2990139-Y
Dates
Type When
Created 18 years, 2 months ago (June 26, 2007, 1:13 a.m.)
Deposited 4 months, 1 week ago (April 23, 2025, 10:55 p.m.)
Indexed 2 days, 18 hours ago (Sept. 3, 2025, 5:50 a.m.)
Issued 18 years, 8 months ago (Jan. 1, 2007)
Published 18 years, 8 months ago (Jan. 1, 2007)
Published Online 18 years, 2 months ago (June 25, 2007)
Published Print 18 years, 8 months ago (Jan. 1, 2007)
Funders 0

None

@article{Airley_2007, title={Hypoxic Regulation of Glucose Transport, Anaerobic Metabolism and Angiogenesis in Cancer: Novel Pathways and Targets for Anticancer Therapeutics}, volume={53}, ISSN={1421-9794}, url={http://dx.doi.org/10.1159/000104457}, DOI={10.1159/000104457}, number={4}, journal={Chemotherapy}, publisher={S. Karger AG}, author={Airley, Rachel E. and Mobasheri, Ali}, year={2007}, pages={233–256} }